Pfizer and Quark Biotech have entered into an agreement under which Pfizer acquires an exclusive worldwide license to Quark’s novel human gene RTP-801 and to molecules that modify its expression or function. RTP-801 is involved in the development of pathologic blood vessels, which accelerate the progression of age-related macular degeneration (AMD). Financial terms of the agreement were not disclosed. AMD is the leading cause of blindness in the developed world affecting about 15 mi...